Follicular lymphoma · 10 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Ofatumumab monotherapy Variant #03 | — | R 512 332 | 28d | ~8.1 mo | — | ~6 | ~R 3 073 989 PFS proxy · indirect | 4 |
Fludarabine and Rituximab (FR) Variant #01 | — | R 34 157 | 28d | — | — | ~6 | ~R 204 943 indirect | — |
FCM Variant #01 | — | R 16 144 | 28d | — | — | ~6 | ~R 96 867 indirect | — |
Fludarabine monotherapy Variant #05 | — | R 13 754 | 28d | ~16.5 mo | ~52.9 mo | ~10 | ~R 137 540 PFS proxy · indirect | 4 |
FMP Variant #01 | — | R 11 931 | 21d | — | — | ~6 | ~R 71 587 indirect | — |
CHOP Variant #20 | — | R 835 | 21d | ~15.5 mo | — | ~6 | ~R 5 011 PFS proxy · indirect | 4 |
131Iodine-Tositumomab monotherapy Variant #01 Partial | — | — | — | — | — | ~1 | — | — |
Umbralisib monotherapy Variant #01 Partial | — | — | 28d | — | — | ~2 | — | — |
Idelalisib monotherapy Variant #01 Partial | — | — | 28d | — | — | ~2 | — | — |
Interferon alfa monotherapy Variant #01 Partial | — | — | 7d | — | — | ~2 | — | — |
10 of 10 regimens shown